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Fig. S1. Immunization with VHHMHCII-SpikeRBD induces high-titer anti-SpikeRBD and 
neutralizing antibodies in C57BL/6J mice. (A). C57BL/6J mice were immunized 
intraperitoneally with adjuvant only, adjuvanted SpikeRBD, or adjuvanted VHHMHCII-SpikeRBD on the 
indicated days. Serum samples were collected as indicated. (B). Total IgG (days -13 and day 14) 
or (C). IgM, IgA, IgG1, and IgG2b (day 14) responses were evaluated from sera of immunized 
mice (n = 4-7/group) by ELISA against recombinant SpikeRBD. ELISA data were presented as 
means ± SEM. (D). Humoral responses in sera of immunized mice were evaluated (n = 4-
7/group) by ELISA for anti-SpikeRBD (K417T, E484K, N501Y mutations) IgG. ELISA data were 
presented as means ± SEM. 
 
 
Fig. S2. Immunization with VHHMHCII-SpikeRBD induces high-titer anti-SpikeRBD and 
neutralizing antibodies in BALB/c mice. (A). C57BL/6J and BALB/c mice were immunized 
intraperitoneally with adjuvant only or adjuvanted VHHMHCII-SpikeRBD on the indicated days. 
Serum samples were collected as indicated. (B). Total IgG or (C). IgM, IgA, IgG1, and IgG2b (day 
14) responses were evaluated from sera of immunized mice (n = 4/group) by ELISA against 
recombinant SpikeRBD. ELISA data were presented as means ± SEM. (D). Humoral responses in 
sera of immunized mice were evaluated (n = 4/group) by ELISA for anti-SpikeRBD (K417T, E484K, 




Fig. S3. Kinetics of humoral immune response upon immunization with 1 or 2 doses of 
adjuvanted VHHMHCII-SpikeRBD. (A). C57BL/6J were immunized intraperitoneally with adjuvant 
only or adjuvanted VHHMHCII-SpikeRBD on the indicated days. Serum samples were collected as 
indicated. Total IgG responses were evaluated from sera of immunized mice (n = 4/group) by 
ELISA against recombinant SpikeRBD. ELISA data were presented as means ± SEM. (B). 
Similarly, IgM, IgA, IgG1, and IgG2b responses were evaluated from sera of immunized mice (n = 
4/group) by ELISA against recombinant SpikeRBD. ELISA data were presented as 
means ± SEM. (C). Humoral responses in sera of immunized mice were evaluated (n = 4/group) 
by ELISA for anti-SpikeRBD (K417T, E484K, N501Y mutations) IgG. ELISA data were presented 
as means ± SEM. (D). Neutralization data for VSV, pseudotyped with the SARS-CoV-2 Spike 
glycoprotein Wuhan Hu-1. All data presented as means ± SEM. n.s. not significant; *p<0.05, 
**p<0.01, ***p<0.001, unpaired t-test with Holm-Sidak adjustment. 
  
Fig. S4. Neutralization of SARS-CoV-2 strain NL2020 following immunization with two 
doses of adjuvanted VHHMHCII-SpikeRBD. (A). Scheme of immunization and bleeding schedule of 
C57BL/6J mice. (B). qRT-PCR-based neutralization assay against SARS-CoV-2 strain /NL/2020     
. Turquoise data points indicate neutralization by anti-Spike monoclonal antibody 47D11. Of note,      
mAB 47D11 (3.14mg/ml) was pre diluted at 1:100 (to 31.4ug/ml) and it was then used at indicated 
dilutions. All data presented as means of technical replicates ± SEM.  
  
 
Fig. S5. Representative gating strategies of SpikeRBD-specific CD4 and CD8 T cell flow 
cytometry analyses. Flow cytometry analyses were conducted on the splenocytes from 
immunized mice in Figure 2, co-cultured for 6 h with or without cocktail of peptides (42 and 47-50) 




Fig. S6. VHHMHCII-SpikeRBD elicits a strong humoral response regardless of route of 
administration, storage temperature, lyophilization, or mouse age.  (A). IgM levels were 
measured against recombinant SpikeRBD following immunization with different routes of 
administration. (B). Anti-SpikeRBD IgM levels upon immunization with vaccines maintained under 
different storage conditions. (C). Anti-SpikeRBD IgM levels in immunized young and old mice. n = 4 
for all conditions, and curves are plotted as means ± SEM of each condition. 
  
 
Fig. S7. Immunization with VHHhMHCII-SpikeRBD induces high-titer anti-SpikeRBD in 
humanized DR4-IE mice. (A). DR4-IE mice were immunized intraperitoneally with adjuvant only 
or adjuvanted VHHhMHCII-SpikeRBD on the indicated days. Serum samples were collected as 
indicated. (B). Total IgG or (C). IgM, IgA, IgG1, and IgG2b (day 14) responses were evaluated 
from sera of immunized mice (n = 3/group) by ELISA against recombinant SpikeRBD. ELISA data 
were presented as means ± SEM. (D). Humoral responses in sera of immunized mice were 
evaluated (n = 3/group) by ELISA for anti-SpikeRBD (K417T, E484K, N501Y mutations) IgG. 
ELISA data were presented as means ± SEM. 
